Skip to main content

Table 4 Safety

From: Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan

 

Avacopan (n = 21)

TEAEs associated with avacopan

10 (47.6%)

Elevated liver enzymes

8 (38.1%)

 AST level, U/L (normal range; 13–30)

142 (135–143)

 ALT level, U/L (normal range; 30–42)

153 (142–183)

Diarrhoea/Nausea

2 (9.5%)

Drug discontinuation due to TEAEs associated with avacopan

9 (42.9%)

Elevated liver enzymes

7 (33.3%)

Diarrhoea/Nausea

2 (9.5%)

Time to drug discontinuation, months

1.6 (1.0–1.9)

  1. Data are presented as number (%) or median (interquartile range)
  2. TEAEs treatment-emergent adverse events, AST aspartate transferase, ALT alanine transaminase
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us